The androgen receptor antagonist apalutamide (ARN) and the complex I inhibitor IACS-010759 (IACS) regulate the process of mitochondrial fission and fusion in prostate cancer, and the combination of the two can increase androgen-sensitive prostate cancer cell death and mitochondrial oxidative stress [176]. This evidence concerns the gene AR and prostate carcinoma.